VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead
Five approved products anchor a diversified portfolio, with BYSANTI and NEREUS launches driving near-term growth. Key clinical readouts for MDD and GLP-1-induced nausea could unlock major new markets, while commercial infrastructure is primed for expansion.Based on Vanda Pharmaceuticals Inc. [VNDA…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.